Sugi Predict

Sugi Predict / Compounds / SCHEMBL1675629

SCHEMBL1675629

SCHEMBL1675629

COc1cc(Br)cc(F)c1[N+](=O)[O-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ PKM P14618 1/20 0.40
▸ GRIN2D O15399 2/20 0.39
▸ GRIN3B O60391 2/20 0.39
▸ GRIN1 Q05586 2/20 0.39
▸ GRIN2A Q12879 2/20 0.39
▸ GRIN2B Q13224 2/20 0.39
▸ GRIN2C Q14957 2/20 0.39
▸ GRIN3A Q8TCU5 2/20 0.39
▸ TDP1 Q9NUW8 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ POLB P06746 2/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30693913 0.89 MAPT (0.36) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1000100 0.87 PKM (0.45) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL21810283 0.83 HTT (0.49) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL972269 0.82 PKM (0.41) MAPTALDH1A1MEN1KMT2APKM
SCHEMBL14387490 0.82 ALOX15 (0.42) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL26834351 0.82 GRIN2D (0.43) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1358844 0.81 TDP1 (0.39) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL27162901 0.81 ACHE (0.41) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL15400557 0.81 PKM (0.41) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL18398574 0.80 MAPT (0.33) MAPTALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743178-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2026-05-20 — — EP disclosed
EP-4743447-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2026-05-20 — — EP disclosed
WO-2026087650-A1 VINYLOXY-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER SANOFI (FR) 2026-04-30 — — WO disclosed
EP-4688751-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS Enanta Pharmaceuticals, Inc. (US) 2026-02-11 — — EP disclosed
EP-4688144-A1 COMPOUNDS AS GLP-1R AGONISTS Terns Pharmaceuticals, Inc. (US) 2026-02-11 — — EP disclosed
US-20250368659-A1 Antiviral Heterocyclic Compounds ENANTA PHARM INC (US) 2025-12-04 — — US disclosed
EP-4638440-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2025-10-29 — — EP disclosed
WO-2025201477-A1 SPIROCYCLIC GSDME INHIBITORS PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) 2025-10-02 — — WO disclosed
US-20250236627-A1 CERTAIN OCTAHYDROFURO[3,4- B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2025-07-24 — — US disclosed
US-12358921-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2025-07-15 — — US disclosed
US-20110082111-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-07 — — US disclosed
US-20110082111-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-07 — — US disclosed
US-20110082111-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-07 — — US disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 — — WO disclosed
EP-2205241-A1 POLO-LIKE KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-07-14 — — EP disclosed
US-20090281092-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 — — US disclosed
US-20090281092-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 — — US disclosed
US-20090281092-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 — — US disclosed
WO-2009042711-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 — — WO disclosed
WO-2009042711-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281092-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK MAPT 1318/4885ALDH1A1 4009/4885MEN1 3731/4885
US-12358921-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 MAPT 4609/4885ALDH1A1 2104/4885MEN1 1056/4885
US-20110082111-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK MAPT 1318/4885ALDH1A1 4009/4885MEN1 3731/4885
US-20250368659-A1 Antiviral Heterocyclic Compounds ACE, HPRT1, ACE2 MAPT 4609/4885ALDH1A1 2104/4885MEN1 1056/4885
US-20250236627-A1 CERTAIN OCTAHYDROFURO[3,4- B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, GPR119 MAPT 4497/4885ALDH1A1 746/4885MEN1 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.